Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
NCT04419272
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
Methylphenidate (MPH) is a stimulant, FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD). It is unknown, however, if stimulants would be of benefit for memory and thinking problems due to epilepsy. In this study, participants will be assigned randomly (i.e., by flip of a coin), to a group that takes MPH and a group that takes a placebo (sugar pill). Participants will not know the group to which they have been assigned. Tests of attention and memory will be completed before taking the study pills and at Week 8.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Epilepsy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- VA Office of Research and Development
- Last updated on ClinicalTrials.gov
- April 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Miami VA Healthcare System, Miami, FL · Miami, FL
Massachusetts · 1
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA · Boston, MA
New York · 1
- VA NY Harbor Healthcare System, New York, NY · New York, NY
Oregon · 1
- VA Portland Health Care System, Portland, OR · Portland, OR
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.